The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01F | Monoclonal antibodies and antibody drug conjugates | |
| 4 | L01FX | Other monoclonal antibodies | |
| 5 | L01FX03 | Catumaxomab |
| Active Ingredient | Description | |
|---|---|---|
| Catumaxomab |
Catumaxomab is a trifunctional rat-mouse hybrid monoclonal antibody that is specifically directed against the epithelial cell adhesion molecule (EpCAM) and the CD3 antigen. The EpCAM antigen is expressed on most cancers especially carcinomas. CD3 is expressed on mature T-cells as a component of the T-cell receptor. A third functional binding site in the Fc-region of catumaxomab enables interaction with accessory immune cells via Fc-gamma receptors. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| KORJUNY Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| REMOVAB Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.